SCHEDULE 13G/A: Bristol Myers Squibb Discloses 1.64% Passive Stake in Q32 Bio Inc.
Beneficial Ownership Report
Bristol Myers Squibb Company has filed an amended Schedule 13G, reporting a 1.64% beneficial ownership stake in Q32 Bio Inc. as of December 31, 2024.
Summary
- Bristol Myers Squibb Co. (Reporting Person) filed an Amendment No. 1 to Schedule 13G concerning Q32 Bio Inc. (Issuer).
- As of December 31, 2024, Bristol Myers Squibb beneficially owned 200,244 shares of Q32 Bio Inc. common stock.
- This ownership represents 1.64% of Q32 Bio Inc.'s outstanding common stock.
- The percentage is calculated based on 12,180,701 shares of common stock outstanding as of November 1, 2024, as reported in Q32 Bio Inc.'s Form 10-Q filed with the SEC on November 7, 2024.
- Bristol Myers Squibb holds sole voting power and sole dispositive power over all 200,244 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive ownership stake, which is neither inherently positive nor negative for the issuer or the reporting person.
Positives
- A major pharmaceutical company, Bristol Myers Squibb, holds a minority stake in Q32 Bio Inc., indicating some level of institutional interest in the company.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the future outlook of Q32 Bio Inc. or Bristol Myers Squibb's investment strategy.
Industry Context
This filing represents a routine disclosure of a passive investment by a large, established pharmaceutical company (Bristol Myers Squibb) in a smaller biotechnology firm (Q32 Bio Inc.). Such filings are common and typically indicate a financial investment rather than a strategic partnership or acquisition intent, especially given the passive nature and the ownership percentage being below 5%.
Stakeholder Impact
- Shareholders of Q32 Bio Inc. may note that a significant institutional investor, Bristol Myers Squibb, holds a minority stake in the company.
Key Dates
| Date | Description |
|---|---|
| November 1, 2024 | Date as of which 12,180,701 shares of Q32 Bio Inc. common stock were reported outstanding. |
| November 7, 2024 | Date Q32 Bio Inc.'s Form 10-Q was filed with the Securities and Exchange Commission. |
| December 31, 2024 | Date of the event which requires the filing of this Schedule 13G statement. |
| February 14, 2025 | Date the Schedule 13G was signed by Bristol Myers Squibb Co. |
Keywords
Q32 Bio Inc., Bristol Myers Squibb, Schedule 13G, beneficial ownership, common stock, pharmaceutical, biotechnology, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.